© Drug Hunter Inc. 2018-2023
Home > GSK620
BD2 domain selective BET inhibitor
oral efficacy in 3 inflammation models
from SBDD of a BD2-selective HTS hit
Science, Mar. 19, 2020
GlaxoSmithKline, Stevenage, UK
GSK620 (GlaxoSmithKline (GSK) oral in vivo BD2 domain selective BET inhibitor)
You don’t have time to read everything, but you can’t afford to fall behind.
Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.
Get ahead now by requesting a trial.
Molecules of the Month
Molecule of the Year